Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
AVADEL PHARMACEUTICALS PLC (AVDL) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/29/2021 GN Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th
04/17/2021 GN Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting
03/04/2021 GN Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2021 Young Investigators Research Forum
03/02/2021 GN Avadel Pharmaceuticals Announces Publication of Once-Nightly FT218 Pharmacokinetic Studies
03/01/2021 GN Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
02/23/2021 GN Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th
02/10/2021 GN Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
12/16/2020 GN Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA
12/07/2020 GN Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice President of Medical and Clinical Affairs
11/23/2020 GN Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences
11/11/2020 GN Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences
09/17/2020 GN Avadel to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
09/11/2020 GN Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference
07/01/2020 GN Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 Million
05/04/2020 GN Avadel Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11th
04/28/2020 GN Avadel Pharmaceuticals Announces Pricing of Public Offering
04/27/2020 GN Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering
03/25/2020 GN Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
02/21/2020 GN Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds
12/17/2019 GN Avadel Pharmaceuticals Completes Enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
12/16/2019 GN Avadel Pharmaceuticals Receives U.S. FDA Approval for Nouress™ (AV001), a Cysteine Hydrochloride Injection for Treating Neonate Patients Requiring Total Parental Nutrition (TPN)
12/10/2019 GN Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors
12/02/2019 GN Avadel Pharmaceuticals Announces Key Appointments to Leadership Team To Support Continued Transformation and the Advancement of FT218
11/25/2019 GN Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
11/21/2019 GN Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences
09/24/2019 GN Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25th
09/23/2019 GN Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019
09/18/2019 GN Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th
07/29/2019 GN Avadel Pharmaceuticals to Report Second Quarter 2019 Financial Results
06/03/2019 GN Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer
05/22/2019 GN Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for AV001
05/08/2019 GN Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results
04/29/2019 GN Avadel Pharmaceuticals to Report First Quarter 2019 Financial Results
03/15/2019 GN Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy